Athersys licenses gastrointestinal stem cell candidate to Pfizer
This article was originally published in Scrip
Executive Summary
Pfizer and Athersys have agreed to develop a stem cell therapy for the treatment of inflammatory bowel disease (IBD) in a $111 million deal. The alliance pushed shares in Athersys up by more than 200% to around $3 per share in early morning trading.